TY - JOUR
T1 - Invasive fungal infections while on voriconazole, liposomal amphotericin B, or micafungin for antifungal prophylaxis in pediatric stem cell transplant patients
AU - Bui, Annie
AU - Nguyen, Veronica
AU - Hsu, Christina
AU - Hyde, Ben
AU - Simms-Waldrip, Tiffany
N1 - Publisher Copyright:
© 2019, Pediatric Pharmacy Advocacy Group, Inc.. All rights reserved.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - OBJECTIVE This study aimed to report the incidence of invasive fungal infections (IFIs) in pediatric hematopoietic stem cell transplant (HSCT) patients who received voriconazole, liposomal amphotericin B (L-AMB), or micafungin for primary antifungal prophylaxis (PAP). METHODS Using data retrospectively collected from institution’s electronic records, this study analyzed the incidence of IFIs in pediatric HSCT patients between November 2012 and November 2016. RESULTS A total of 103 patients were screened. Of the 84 patients who met inclusion criteria, 76.2%, 29.8%, and 19% patients received voriconazole, L-AMB, and micafungin, respectively. The incidence of overall IFIs was 2.08 per 1000 prophylaxis days. There were 2 mold infections identified in 2 patients. Among 3 antifungal agents, the rates of IFIs were 2.67 per 1000 prophylaxis days in L-AMB group, 2.08 per 1000 prophylaxis days in micafungin group, and 1.17 per 1000 prophylaxis days in voriconazole group. CONCLUSION Patients who received L-AMB or micafungin had higher rates of IFIs than those who received voriconazole for PAP.
AB - OBJECTIVE This study aimed to report the incidence of invasive fungal infections (IFIs) in pediatric hematopoietic stem cell transplant (HSCT) patients who received voriconazole, liposomal amphotericin B (L-AMB), or micafungin for primary antifungal prophylaxis (PAP). METHODS Using data retrospectively collected from institution’s electronic records, this study analyzed the incidence of IFIs in pediatric HSCT patients between November 2012 and November 2016. RESULTS A total of 103 patients were screened. Of the 84 patients who met inclusion criteria, 76.2%, 29.8%, and 19% patients received voriconazole, L-AMB, and micafungin, respectively. The incidence of overall IFIs was 2.08 per 1000 prophylaxis days. There were 2 mold infections identified in 2 patients. Among 3 antifungal agents, the rates of IFIs were 2.67 per 1000 prophylaxis days in L-AMB group, 2.08 per 1000 prophylaxis days in micafungin group, and 1.17 per 1000 prophylaxis days in voriconazole group. CONCLUSION Patients who received L-AMB or micafungin had higher rates of IFIs than those who received voriconazole for PAP.
KW - Antifungal prophylaxis
KW - Invasive fungal infection
KW - Liposomal amphotericin B
KW - Micafungin
KW - Voriconazole
UR - http://www.scopus.com/inward/record.url?scp=85068874191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068874191&partnerID=8YFLogxK
U2 - 10.5863/1551-6776-24.3.220
DO - 10.5863/1551-6776-24.3.220
M3 - Article
C2 - 31093021
AN - SCOPUS:85068874191
SN - 1551-6776
VL - 24
SP - 220
EP - 226
JO - Journal of Pediatric Pharmacology and Therapeutics
JF - Journal of Pediatric Pharmacology and Therapeutics
IS - 3
ER -